EDC for Phase 1a Clinical Trials

EDC for Phase 1a trials: first-in-human safety, dose escalation, and PK/PD in one platform with 21 CFR Part 11–aligned controls and audit trails.

21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required

Typical Phase 1a cohort flow in practice

Most Phase 1a programs start with a small sentinel group within the first cohort, followed by staged dosing of the remaining participants once initial safety data are reviewed. Subsequent cohorts may increase the dose or adjust the schedule based on predefined criteria. Your EDC needs to make it easy to see which cohort each participant belongs to, where they are in the schedule, and which assessments are due next—without relying on offline trackers or spreadsheets.

  • Define cohorts and dose levels explicitly so each participant is clearly assigned
  • Schedule visits and assessments around sentinel dosing and staged enrollment
  • Use queries and review flags to highlight data that must be checked before dose escalation
  • Keep cohort status, safety findings, and next steps visible to the study team in one place

Preparing for safety review and dose-escalation meetings

Dose-escalation decisions often happen in formal safety review meetings with investigators, medical monitors, and sponsor representatives. Ahead of these meetings, teams typically prepare listings of AEs, conmeds, labs, ECGs, and PK parameters for the cohort under review. Capture supports that workflow by giving you structured data that can be exported consistently, so your biostatistics or pharmacometrics teams can generate summaries without cleaning multiple spreadsheets.

  • Export cohort-specific data cuts for AEs, labs, ECGs, and PK summaries
  • Track which data have been reviewed and which queries remain open before the meeting
  • Document cohort decisions and protocol updates in your study files alongside the EDC audit trail

How Phase 1a teams actually use Capture.Study

On the Capture side, Phase 1a teams typically start in a sandbox, using the same public-facing platform you see on the homepage and demo page, then promote a validated configuration to production for regulated studies. Study builders define cohorts, visits and forms in the browser; coordinators and investigators log in via the same interface they use for other early-phase trials; and participants can complete any required ePRO tasks from mobile devices without installing a separate app.

  • Study builders configure a draft Phase 1a study in a sandbox environment before validation
  • Once qualified, the same configuration is used for the live study with production controls
  • Investigators, coordinators and monitors access the study via the same Capture.Study web app as other trials
  • Participants can complete any protocol-required questionnaires via mobile-friendly web links when ePRO is in scope

Overview

EDC for Phase 1a Clinical Trials

Phase 1a (or Phase 1 first-in-human) trials evaluate initial safety, tolerability, and pharmacokinetics in healthy volunteers. These studies are the first time an investigational product is administered to humans, so consent, safety monitoring, and data integrity are under close regulatory and ethics scrutiny. Cohort-based dose escalation, sentinel dosing, intensive cardiac and laboratory assessments, and careful follow-up of any adverse events all have to be documented in a way that is traceable and easy to review. Many Phase 1a programs also plan for adaptive changes based on emerging safety or PK findings, which means the underlying study build must be able to accommodate protocol amendments without compromising the audit trail. EDC for Phase 1a must support dose-escalation logic, dense PK and safety sampling, strict consent versioning and electronic signature, and adverse event capture with full auditability—while remaining fast to deploy and easy to amend as the protocol evolves. Capture provides one platform for eConsent, EDC, ePRO, and safety with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure, so you can run Phase 1a and FIH studies without the implementation burden of enterprise systems or the need to orchestrate multiple disconnected tools. The same configuration approach can be reused or adapted across multiple FIH programs, so teams don’t have to start from scratch each time they bring a new asset into humans for the first time.

Why Phase 1a is different

Phase 1a studies are the first time a drug is given to humans. Protocols are carefully controlled, with close safety monitoring and often cohort-based dose escalation. Consent must be versioned and signed with a clear audit trail; safety and PK data must be complete and traceable. Your EDC should support these workflows without the overhead of systems built for large, multi-site Phase 3 trials. Sponsors and CROs need to move quickly from approval to first dose, with confidence that the system supports regulatory and ethics expectations for data integrity and participant protection. It is common for governance bodies to ask for clear line-of-sight from consent and eligibility through dosing decisions and subsequent safety events; that is much easier when eConsent, CRFs, and AE capture all live in the same system with one audit trail. Phase 1a teams also benefit from being able to simulate or test builds in a sandbox environment before locking the configuration for live use.

Common Phase 1a workflow

  • Protocol and consent document finalization with ethics and regulatory approvals
  • Single or few sites; fast activation and training
  • Screening and eligibility checks against inclusion/exclusion criteria
  • Informed consent (electronic) with version control and e-signature
  • Dose administration and PK/safety sampling at defined time points
  • Adverse event and concomitant medication capture with severity and causality
  • Cohort review, safety review, and dose-escalation decisions
  • Ongoing data review and query resolution with investigators and monitors
  • Periodic safety review meetings and potential cohort amendments based on emerging data
  • Database lock and export for PK and safety analysis

Traditional tool pain points

  • Lengthy vendor selection and implementation delaying first dose and burning runway
  • Rigid systems that make protocol and consent updates slow and costly
  • High cost for small volunteer cohorts and per-seat pricing that doesn’t fit FIH scale
  • Overbuilt features and complexity for early FIH needs
  • Disconnected consent, EDC, and safety tools with no single audit trail
  • Slow response from vendors when you need a quick build or amendment
  • Limited support for cohort-based review and decision-making within the same platform

How Capture supports Phase 1a

  • Single platform for EDC, eConsent, ePRO, and safety so you can go live quickly and keep one audit trail
  • Flexible visit and form design for dose escalation, cohorts, and PK sampling schedules
  • Electronic consent with versioning, e-signature, and full audit trail for each consent event
  • Adverse event capture with severity, causality, follow-up, and full audit history and role-based access
  • 21 CFR Part 11–aligned controls: e-signatures, comprehensive audit trails, and access controls
  • HIPAA-aligned infrastructure for participant data and PHI
  • Documentation and support for sponsor validation and UAT (Enterprise) when required for regulated studies
  • Configurable dashboards and filters so medical monitors can focus on cohorts, dose levels, and key safety signals

Related

Clinical trial softwareAffordable EDC for clinical trials

FAQ

Questions we hear a lot

Is Capture used for first-in-human trials?
Yes. Capture is used by sponsors and CROs for Phase 1a and other early-phase, first-in-human studies. The platform supports consent, CRFs, safety, and PK-style data collection with the controls and auditability needed for regulated FIH trials. We provide documentation to support sponsor validation and UAT for Enterprise customers.
How do you support dose escalation?
You can model visits and forms around cohorts and dose levels. Logic and forms can be updated to support protocol amendments (e.g., new cohorts or dose levels). All changes are recorded in the audit trail for regulatory review. Capture is designed for the kind of iteration common in Phase 1a without long change-control cycles.
What compliance standards does Capture meet?
Capture is designed with 21 CFR Part 11–aligned controls (electronic signatures, audit trails, access control) and HIPAA-aligned security. We do not claim “validated” without sponsor-led validation; we provide documentation to support sponsor validation and UAT for regulated studies as part of Enterprise offerings.
How is consent handled for Phase 1a?
Capture includes electronic consent with version control and electronic signature. Each consent event is recorded in the audit trail. You can support multiple consent versions if the protocol or ICF is amended, so ethics and regulatory requirements for informed consent are met with full traceability.
Can we manage screening logs and screen failures in Capture?
Yes. You can configure forms to capture prescreening and screening data, including reasons for screen failure. This helps teams understand feasibility during Phase 1a while keeping all activity in the same audit trail as the main study.
Can we prototype our FIH build before going live?
Many teams use a sandbox or non-production environment to prototype and test their Phase 1a / FIH build. Capture supports this approach so you can test cohort logic, visit schedules, and consent flows before you finalize the configuration for live use.
Can we separate test and production environments?
Yes. Sponsors typically use a non-production environment for configuration and testing, and a separate production environment for live data collection. Each environment has its own audit trail so you can document validation activities separately from operational use.
How do monitors access Phase 1a studies?
Monitors receive role-based access to the same Capture.Study web interface, with permissions scoped to review only. They can see cohort status, participant data, and queries, and their actions are tracked in the audit trail.
Does Capture support combined Phase 1/2 designs?
Yes. You can configure studies that span multiple phases (e.g., Phase 1/2) by defining appropriate visits, cohorts, and forms. Teams sometimes start with a Phase 1a/1b configuration and extend it into early Phase 2 using the same platform.
Can we export Phase 1a data in formats our analysis team expects?
Yes. Capture supports exports suitable for pharmacokinetic and safety analyses. For regulated programs, sponsors typically align export structures with their internal standards and validation plans; we provide documentation to support that alignment as part of Enterprise offerings.

Ready to see Capture in action?

Explore the platform with a free sandbox. No sales call required.